vs
STANDARD BIOTOOLS INC.（LAB）与NORTECH SYSTEMS INC（NSYS）财务数据对比。点击上方公司名可切换其他公司
NORTECH SYSTEMS INC的季度营收约是STANDARD BIOTOOLS INC.的1.6倍（$30.3M vs $19.6M），NORTECH SYSTEMS INC净利率更高（3.0% vs -177.4%，领先180.4%），NORTECH SYSTEMS INC同比增速更快（5.9% vs -11.5%），NORTECH SYSTEMS INC自由现金流更多（$5.5M vs $-23.1M），过去两年NORTECH SYSTEMS INC的营收复合增速更高（-5.9% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Nortech Systems Inc是一家全球电子制造服务提供商，为医疗科技、工业自动化、航空航天国防、交通运输等领域客户提供产品设计、原型制作、规模生产、供应链管理等全链路解决方案，主打符合行业规范的高可靠性电子组件与装配产品。
LAB vs NSYS — 直观对比
营收规模更大
NSYS
是对方的1.6倍
$19.6M
营收增速更快
NSYS
高出17.4%
-11.5%
净利率更高
NSYS
高出180.4%
-177.4%
自由现金流更多
NSYS
多$28.6M
$-23.1M
两年增速更快
NSYS
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $30.3M |
| 净利润 | $-34.7M | $897.0K |
| 毛利率 | 48.5% | 16.7% |
| 营业利润率 | -168.5% | 3.0% |
| 净利率 | -177.4% | 3.0% |
| 营收同比 | -11.5% | 5.9% |
| 净利润同比 | -28.8% | 160.7% |
| 每股收益（稀释后） | $-0.09 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABNSYS
| Q4 25 | — | $30.3M | ||
| Q3 25 | $19.6M | $30.5M | ||
| Q2 25 | $21.8M | $30.7M | ||
| Q1 25 | $40.8M | $26.9M | ||
| Q4 24 | — | $28.6M | ||
| Q3 24 | $22.1M | $31.4M | ||
| Q2 24 | $22.5M | $33.9M | ||
| Q1 24 | $45.5M | $34.2M |
净利润LABNSYS
| Q4 25 | — | $897.0K | ||
| Q3 25 | $-34.7M | $-146.0K | ||
| Q2 25 | $-33.5M | $313.0K | ||
| Q1 25 | $-26.0M | $-1.3M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | $-26.9M | $-739.0K | ||
| Q2 24 | $-45.7M | $157.0K | ||
| Q1 24 | $-32.2M | $765.0K |
毛利率LABNSYS
| Q4 25 | — | 16.7% | ||
| Q3 25 | 48.5% | 16.5% | ||
| Q2 25 | 48.8% | 15.8% | ||
| Q1 25 | 48.4% | 11.4% | ||
| Q4 24 | — | 9.9% | ||
| Q3 24 | 54.9% | 12.2% | ||
| Q2 24 | 46.1% | 13.6% | ||
| Q1 24 | 53.1% | 15.9% |
营业利润率LABNSYS
| Q4 25 | — | 3.0% | ||
| Q3 25 | -168.5% | 3.1% | ||
| Q2 25 | -118.1% | 2.4% | ||
| Q1 25 | -80.8% | -6.0% | ||
| Q4 24 | — | -4.3% | ||
| Q3 24 | -120.9% | -1.5% | ||
| Q2 24 | -134.5% | 1.0% | ||
| Q1 24 | -132.2% | 3.4% |
净利率LABNSYS
| Q4 25 | — | 3.0% | ||
| Q3 25 | -177.4% | -0.5% | ||
| Q2 25 | -153.7% | 1.0% | ||
| Q1 25 | -63.8% | -4.9% | ||
| Q4 24 | — | -5.2% | ||
| Q3 24 | -122.0% | -2.4% | ||
| Q2 24 | -203.3% | 0.5% | ||
| Q1 24 | -70.6% | 2.2% |
每股收益（稀释后）LABNSYS
| Q4 25 | — | $0.32 | ||
| Q3 25 | $-0.09 | $-0.05 | ||
| Q2 25 | $-0.09 | $0.12 | ||
| Q1 25 | $-0.07 | $-0.48 | ||
| Q4 24 | — | $-0.51 | ||
| Q3 24 | $-0.07 | $-0.27 | ||
| Q2 24 | $-0.12 | $0.05 | ||
| Q1 24 | $-0.27 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $1.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $34.5M |
| 总资产 | $539.6M | $71.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABNSYS
| Q4 25 | — | $1.7M | ||
| Q3 25 | $129.4M | $1.3M | ||
| Q2 25 | $158.6M | $652.0K | ||
| Q1 25 | $150.9M | $1.2M | ||
| Q4 24 | — | $916.0K | ||
| Q3 24 | $210.6M | $1.2M | ||
| Q2 24 | $269.8M | $1.5M | ||
| Q1 24 | $287.1M | $4.0M |
总债务LABNSYS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABNSYS
| Q4 25 | — | $34.5M | ||
| Q3 25 | $399.7M | $33.4M | ||
| Q2 25 | $424.5M | $33.4M | ||
| Q1 25 | $454.6M | $32.8M | ||
| Q4 24 | — | $34.0M | ||
| Q3 24 | $489.3M | $35.7M | ||
| Q2 24 | $510.3M | $36.1M | ||
| Q1 24 | $577.3M | $36.0M |
总资产LABNSYS
| Q4 25 | — | $71.9M | ||
| Q3 25 | $539.6M | $74.8M | ||
| Q2 25 | $557.0M | $74.8M | ||
| Q1 25 | $579.6M | $73.5M | ||
| Q4 24 | — | $72.4M | ||
| Q3 24 | $681.5M | $77.0M | ||
| Q2 24 | $708.7M | $76.3M | ||
| Q1 24 | $777.7M | $75.5M |
负债/权益比LABNSYS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $5.6M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $5.5M |
| 自由现金流率自由现金流/营收 | -118.1% | 18.0% |
| 资本支出强度资本支出/营收 | 4.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 6.25× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $2.1M |
8季度趋势，按日历期对齐
经营现金流LABNSYS
| Q4 25 | — | $5.6M | ||
| Q3 25 | $-22.2M | $-92.0K | ||
| Q2 25 | $-20.7M | $157.0K | ||
| Q1 25 | $-30.3M | $-2.9M | ||
| Q4 24 | — | $793.0K | ||
| Q3 24 | $-27.9M | $-1.6M | ||
| Q2 24 | $-39.0M | $-4.3M | ||
| Q1 24 | $-62.5M | $2.8M |
自由现金流LABNSYS
| Q4 25 | — | $5.5M | ||
| Q3 25 | $-23.1M | $-242.0K | ||
| Q2 25 | $-22.6M | $58.0K | ||
| Q1 25 | $-35.3M | $-3.2M | ||
| Q4 24 | — | $503.0K | ||
| Q3 24 | $-30.1M | $-1.6M | ||
| Q2 24 | $-41.0M | $-4.6M | ||
| Q1 24 | $-63.3M | $2.1M |
自由现金流率LABNSYS
| Q4 25 | — | 18.0% | ||
| Q3 25 | -118.1% | -0.8% | ||
| Q2 25 | -103.6% | 0.2% | ||
| Q1 25 | -86.6% | -11.9% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | -136.4% | -5.2% | ||
| Q2 24 | -182.2% | -13.5% | ||
| Q1 24 | -138.9% | 6.1% |
资本支出强度LABNSYS
| Q4 25 | — | 0.5% | ||
| Q3 25 | 4.5% | 0.5% | ||
| Q2 25 | 8.7% | 0.3% | ||
| Q1 25 | 12.4% | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | 10.2% | 0.1% | ||
| Q2 24 | 8.6% | 0.8% | ||
| Q1 24 | 1.7% | 2.2% |
现金转化率LABNSYS
| Q4 25 | — | 6.25× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -27.30× | ||
| Q1 24 | — | 3.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
NSYS
| Medical Imaging | $11.4M | 37% |
| Medical Device | $8.0M | 26% |
| Industrial | $7.3M | 24% |
| Aerospace And Defense | $3.7M | 12% |
